Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years and ≤75 years in age~* Patients with relapsed or refractory AML~* No more than one prior stem cell transplant~* Has not received the chemotherapy regimen to be used for induction on this trial~* Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial~Exclusion Criteria:~* Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.~* Active signs or symptoms of CNS involvement by malignancy.~* Stem cell transplantation ≤4 months prior to dosing.~* Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.~* Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.~* Inadequate organ function.~* Abnormal liver function.~* Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.~* Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min).~* Uncontrolled acute life-threatening bacterial, viral, or fungal infection.~* Clinically significant cardiovascular disease.~* Major surgery within 4 weeks of dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Uproleselan (GMI-1271) (Type: EXPERIMENTAL): Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
- Placebo (Saline, 0.9% Sodium Chloride) (Type: PLACEBO_COMPARATOR): Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)

Based on this trial design, predict the completion outcome and termination type (if applicable).